CXCL10 is secreted by cancer cells in vitro in response to inflammatory stimuli [5]; and in “immunoreactive” ovarian tumours, with increased relative expression of CXCL10 and CXCR3, there is increased recruitment of T-lymphocytes and subsequent positive impact on survival [24,25,26]. Here, CXCR3 is linked to cancer.